Biogen Inc BIIB traded sharply higher on Tuesday on better than expected earnings and positive news about its Alzheimer's drug. The company surprised investors by revealing that it will seek the regulatory approval of its Alzheimer's treatment.
Jon Najarian noticed some unusual options activity in the name after the sharp move higher. He said on CNBC's "Fast Money Halftime Report" that options traders were selling the October $300 calls in Biogen. Around 5,000 contracts were sold in the first half of the session on Tuesday as traders were betting that the stock won't continue to move higher, above $300.
Related Links:
Biogen Plans Filing For Failed Alzheimer's Drug After New Analysis
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
